ChromaDex Reports Second Quarter 2017 Financial Results -Company Reports Revenue of $5.3 Million for Q2 2017- - Continued Progress on Building a Consumer Products Platform Around TruNiagen&#xAE

ChromaDex Reports Second Quarter 2017 Financial

-Company Reports Revenue of $5.3 Million for Q2 2017-

- Continued Progress on Building a Consumer Products Platform

IRVINE, Calif., August 10, 2017 ChromaDex Corp.

(NASDAQ: CDXC), an innovator of

proprietary health, wellness and nutritional ingredients, that

creates science-based solutions to dietary supplement, food and

beverage, skin care, sports nutrition, and pharmaceutical products,

announced today the financial results for the quarter ended July 1,

Jaksch, Jr., CEO and co-founder of ChromaDex commented, We

are the innovator of nicotinamide riboside and have positioned the

company as the gatekeeper of the emerging NAD+ precursor market.

During the second quarter we have significantly strengthened our

balance sheet, forged strategic relationships for international

opportunities and began a strategic transformation. Most

importantly, the supporting science continues to build and we

eagerly await the upcoming publication of two additional human

trials on nicotinamide riboside (NR) in the near

Fried, President and Chief Strategy Officer of ChromaDex added,

ChromaDex is making excellent progress in our mission to

grow from a strong science based ingredient company to a vertically

integrated anti-aging platform company focusing on

precursors. Our consumer brand, TruNiagen, is poised to deliver

excellent results in the near future."

Results of operations for the three months ended July 1,

three months ended July 1, 2017 ( Q2 2017 ), ChromaDex

reported net sales of $5.3 million, compared to $8.8 million for

the three months ended July 2, 2016 ( Q2

ingredients segment generated net sales of $3.0 million for Q2

2017, compared to $6.2 million for Q2 2016, the decrease largely as

a result of terminating our largest customer during fiscal year

core standards and services segment posted net sales of $2.3

million for Q2 2017, compared to $2.6 million for Q2 2016. Since

the year ended December 31, 2016, ChromaDex has made operational

changes to merge its scientific and regulatory consulting segment

into the core standards and services segment.

loss attributable to common stock holders for Q2 2017 was $2.8

million or ($0.07) per share, which included a one-time loss of

$746,000 from ongoing litigation, as compared to a net loss of

approximately $83,000 or ($0.00) per share for Q2 2016. Adjusted

EBITDA, a non-GAAP measure, was ($2.1 million) for Q2 2017,

compared to adjusted EBITDA of $0.5 million for Q2 2016. The Basic

and Diluted Adjusted EBITDA per share for Q2 2017 was ($0.05)

versus $0.01 for Q2 2016.

Recent Company highlights include:

Company sponsored the

Federation of American Societies for Experimental Biology (FASEB)

2017 conference for NAD+ Metabolism and

Company appointed Dr. Rudolph

Tanzi, Vice-Chair of Neurology and Director of the Genetics and

Aging Research Unit at Massachusetts General Hospital, and the

Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard

Medical School, to the Scientific Advisory Board

Company signed a new,

exclusive patent license and research agreement with The Scripps

Research Institute (TSRI), gaining access to groundbreaking,

pre-clinical discoveries by Dr. Brunie Felding.

Company announced that Charles Brenner, PhD,

the Roy J. Carver Chair and Head of Biochemistry at the University

of Iowa Carver College of Medicine and current ChromaDex Scientific

Advisory Board member, has been appointed Chief Scientific

Company announced the first launch of

nicotinamide riboside

(NR) into the functional food space.

Company announced the closing of the

$16.4 million second tranche of the strategic investment of up to

$25 million led by Hong Kong business leader Mr. Li

Company announced that it entered into a

securities purchase agreement, pursuant to which the Company sold

$3.5 million of its common stock, with the possibility of selling

up to an additional $21.5 million of its common stock in future

tranches, in a private placement led by Hong Kong business leader

Mr. Li Ka-shing with Horizons

Investor Conference Call

management will host an investor conference call to discuss the

year end results and provide a general business update on Thursday,

August 10, at 4:30 p.m. ET.

should call in at least 10 minutes prior to the call. The dial-in

information is as follows:

earnings press release, accompanying financial exhibits and webcast

replay will all be available on the Investor Relations section of

the Company website, www.chromadex.com.

About Non-GAAP Financial Measures

non-GAAP financial measures exclude interest, tax, depreciation,

amortization and share-based compensation. ChromaDex used

these non-GAAP measures when evaluating its financial results as

well as for internal resource management, planning and forecasting

purposes. These non-GAAP measures should not be viewed in isolation

from or as a substitute for ChromaDex's financial results in

accordance with GAAP. A reconciliation of GAAP to non-GAAP measures

is attached to this press release.

its complementary business units to discover, acquire, develop and

commercialize patented and proprietary ingredient technologies that

address the dietary supplement, food, beverage, skin care and

pharmaceutical markets. In addition to our ingredient technologies

unit, we also have business units focused on natural product fine

chemicals (known as "phytochemicals"), chemistry and analytical

testing services, and product regulatory and safety consulting. As

a result of our relationships with leading universities and